Amber Albaugh
Oncology · Lecanto, FLNPI 1437798402
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,360, 8.2 times the $408 reported in 2021.
Across 342 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$777
- Novartis$665
- Merck$578
- Daiichi Sankyo Inc.$567
- Astellas Pharma US Inc$436
- GSK$419
- plus $5K from 48 others
What the payments were for
- Food & beverage$7,94491%
- Education$8189%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,762 in reported general payments places this provider in the 70th percentile of 24 oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $8,625 |
| Ondansetron OdtOndansetron | 46 | $1,769 |
| Prochlorperazine Maleate | 75 | $1,665 |
| Letrozole | 35 | $1,006 |
| Hydroxyurea | 41 | $964 |
| Dexamethasone | 31 | $847 |
| Acyclovir | 17 | $505 |
| Anastrozole | 35 | $439 |
| Levothyroxine Sodium | 27 | $382 |
| Pantoprazole Sodium | 12 | $211 |
| Prednisone | 16 | $176 |
| Potassium Chloride | 18 | $165 |
| Allopurinol | 16 | $132 |
| Warfarin Sodium | 14 | $94 |
| Gabapentin | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $260 | $8,62515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 oncology providers in Florida.
Other oncology in Lecanto
- Sara BeelerTampa$337K
- Michelle RampersadSebring$34K
- Janell VerkadenOrmond Beach$19K
- Kimberly TopeTampa$16K
- Aaron DohenySt Petersburg$14K
- Naima Vera-SommersTampa$11K
- Natalie GessnerClearwater$8K
- Melissa BlandfordHudson$6K
- Glenda KaminskiLakeland$5K
- Lee PavelBonita Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.